Apogee Therapeutics: Two Shots A Year, One Shot At Disruption (NASDAQ:APGE)

APGE stock stays a Buy on strong Phase 2 atopic dermatitis data for zumilokibart, infrequent dosing edge, and DCF $73 target—read key risks & catalysts.

You are being redirected to the original discussion. Please continue if you want to read the full post.

Continue to original article

You will be redirected in 3 seconds.